The Taiwan Food and Drug Administration (TFDA) has been re-elected as Chair of the Global Harmonization Working Party (GHWP) Working Group 3 (WG3) on Pre-market: Software as a Medical Device (SaMD). This renewed mandate underscores Taiwan’s leadership in advancing international regulatory convergence, particularly in the rapidly evolving field of artificial intelligence (AI)-enabled SaMD.

 

  GHWP WG3 plays a pivotal role in shaping global regulatory frameworks for SaMD, including AI/ML-based technologies that are transforming healthcare delivery. Under TFDA’s chairmanship, the group has successfully developed guidance documents and white papers that support regulators, industry, and healthcare providers in ensuring patient safety while fostering innovation.

 

  The re-election reflects the confidence of GHWP members in TFDA’s ability to continue steering collaborative efforts. Over the past term, WG3 has made significant progress in clarifying definitions, risk categorization, and lifecycle management approaches for AI-driven SaMD. These achievements have laid the foundation for greater alignment among regulatory authorities across Asia, South America, and beyond.

Looking ahead, TFDA will focus on three strategic priorities:

Advancing Cutting-Edge Technology SaMD Regulatory Frameworks: Building consensus on innovative new algorithms, transparency, and cybersecurity pre-market requirements to ensure safe and effective deployment of cutting-edge technology SaMD.

Strengthening International Collaboration: Enhancing dialogue among regulators, industry stakeholders, and academic experts to accelerate harmonization and minimize regulatory fragmentation.

Capacity Building and Education: Supporting GHWP members with training programs, workshops, or technical resources to improve regulatory readiness and foster trust in emerging technologies.

 

  The continued leadership of TFDA in WG3 highlights the nation’s commitment to international regulatory harmonization and its proactive role in shaping the future of medical technology governance. With AI-driven SaMD increasingly integrated into clinical practice, harmonized guidance is essential to ensure equitable access, safety, and public confidence worldwide. As GHWP WG3 enters its new term, TFDA reaffirms its dedication to fostering collaboration, transparency, and innovation.